Creative Planning Buys 9,866 Shares of Avantor, Inc. (NYSE:AVTR)

Creative Planning increased its position in shares of Avantor, Inc. (NYSE:AVTR) by 54.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,136 shares of the company’s stock after purchasing an additional 9,866 shares during the quarter. Creative Planning’s holdings in Avantor were worth $728,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after acquiring an additional 1,391 shares during the period. UMB Bank n.a. purchased a new position in shares of Avantor in the third quarter worth approximately $49,000. GAMMA Investing LLC lifted its holdings in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after purchasing an additional 1,285 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Avantor by 278.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after purchasing an additional 3,700 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Trading Down 0.3 %

Avantor stock opened at $22.31 on Monday. Avantor, Inc. has a 12 month low of $17.46 and a 12 month high of $28.00. The stock has a market cap of $15.18 billion, a price-to-earnings ratio of 48.50, a price-to-earnings-growth ratio of 2.70 and a beta of 1.35. The business has a 50 day moving average price of $25.20 and a two-hundred day moving average price of $24.17. The company has a quick ratio of 1.05, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AVTR. TD Cowen boosted their target price on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. UBS Group dropped their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Barclays reduced their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Morgan Stanley boosted their price target on shares of Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Finally, Robert W. Baird lowered their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.57.

Insider Buying and Selling

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.